Navigation Links
Wake Pharma US, Inc. Announces the Appointment of Kim Eldridge as Coordinator & Clinical Wound Specialist Educator
Date:11/13/2009

Wake Pharma US, Inc. (Chicago, IL) is very pleased to announce the appointment of Kim Eldridge RNFA, CFCN, WCC as Coordinator & Clinical Wound Specialist Educator. Kim Eldridge, Registered Nurse, with over 10 years of clinical experience in complex wound care, is a pioneer in the field of wound care; and is dedicated to providing the highest standards of care, improving clinical outcomes, emphasizing patient education, and ensuring healthcare accessibility and cost-efficiency.

(PRWEB) November 13, 2009 --

Wake Pharma US, Inc. (Chicago, IL) is very pleased to announce the appointment of Kim Eldridge RNFA, CFCN, WCC as Coordinator & Clinical Wound Specialist Educator.

Kim Eldridge, Registered Nurse, was born and raised in Meridian, Mississippi, and has over 10 years of clinical experience in complex wound care. Her commitment to provide the highest standards of wound care, while improving clinical outcomes and emphasizing patient education, and her passion for ensuring healthcare accessibility and cost-efficiency, make Kim a pioneer in the field of wound care.

Kim has been a surgical nurse for over 17 years. She works exclusively with a general surgeon who specializes in wound care, hyperbaric therapy, and limb salvage. She provides surgical wound care in both acute and long term settings, and also consults for major wound care companies and organizations nationwide. She has published several posters and articles in the field of wound care education. Kim is a Registered Nurse First Assistant, and is a certified surgical, foot care and wound care nurse.

Maggie Jankowski, COO of Wake Pharma US, Inc. commented, “Kim Eldridge has been an invaluable resource to the Wound Be Gone® brand. Her clinical insight and experience has been a tremendous asset to our development team. We believe that Kim Eldridge, RN, will help us accelerate the growth of our product line.”

Kim Eldridge stated, “I am very pleased to accept the position of Coordinator & Clinical Wound Specialist Educator and to have the opportunity to contribute to the company’s clinical mission. My clinical experience with Wound Be Gone® has produced impressive results with improved wound healing trajectories. Wound Be Gone® is placing wound care into the hands of people who might otherwise suffer or whose wound problems might escalate to need for expensive, invasive medical intervention.”

Wound-Be-Gone® is a novel hydrophilic gel that has demonstrated enhanced wound healing in varied clinical settings with both acute and chronic wounds. The mechanism of action is related to a decrease in inflammatory mediators due to the active scavenging of oxygen free radicals. Visit www.woundbegone.com for more details.

About Wake Pharma US, Inc:

Wake Pharma US, Inc. is an innovative and international company with its own manufacturing facility located in the Czech Republic (European Union). Wake Pharma US, Inc specializes in developing, marketing and distribution of revolutionary and unique products to the health marketplace. For further information about Wake Pharma US, Inc please visit our website at www.wakepharmaus.com

###

Read the full story at http://www.prweb.com/releases/2009/11/prweb3194034.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
5. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
8. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
9. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
11. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Wake Pharma US, Inc. Announces the Appointment of Kim Eldridge as Coordinator & Clinical Wound Specialist Educator 
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... miniature, folded, pharmaceutical inserts and outserts. As a means of expanding capabilities ... addition will enable Flottman to individually code professional inserts (PIs) and patient package ...
(Date:12/9/2016)... NY (PRWEB) , ... December 09, 2016 , ... ... and Drug Dependence, Inc. (NCADD) is recommending the film Whispering Spirits ... and the District of Columbia as an education tool in the war against teen ...
(Date:12/9/2016)... ... December 09, 2016 , ... An inventor from Cana, Va., wanted ... all types of amusement park rides. , The patent-pending SAFETY STRAP FOR AMPUTEES improves ... use and could be set up in a matter of minutes, or even seconds. ...
(Date:12/9/2016)... ... 09, 2016 , ... The Holy Name Medical Center Foundation ... on December 3rd, to benefit Holy Name Medical Center's programs and services. More ... over $1 million - the largest event in the Center's history, both in ...
(Date:12/9/2016)... ... December 09, 2016 , ... "I had a terrible time trying to get ... thought that if the nebulizer had a more child-friendly design, then children would be ... developed the patent-pending NEBY to avoid the need to deliver medication via a nebulizer ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... -- Australia Glaucoma Surgery Devices Market Outlook to ... Glaucoma Surgery Devices Market Outlook to 2022", provides ... Devices market. The report provides value, in millions ... prices (USD) within market segement - Glaucoma Drainage ... and distribution shares data for each of these ...
(Date:12/8/2016)... 2016 KEY FINDINGS The global ... 2017-2023. Various reasons for growth of the medical lifting ... of chronic diseases, high recovery cost of injuries and ... Medical lifting sling refers to an assistive device that ... slings connect to the lift and hold the patient. ...
(Date:12/8/2016)... Lilly and Company (NYSE: LLY ) today ... at the 9 th Clinical Trials on Alzheimer,s ... meet the primary endpoint in the EXPEDITION3 clinical trial, ... dementia due to Alzheimer,s disease (AD), and Lilly will ... of mild dementia due to AD. ...
Breaking Medicine Technology: